2027 ASCCP Scientific Meeting on Anogenital and HPV-Related Diseases

Through an array of educational offerings, the 2025 ASCCP Scientific Meeting on Anogenital and HPV-Related Diseases will bring together healthcare professionals from different backgrounds and experience levels who are interested in staying informed about the latest research dedicated to improving clinical outcomes and to reducing the burden of anogenital and HPV-related diseases around the world. Educational Objectives: Integrate into practice new insights from the latest research on prevention, diagnosis and management of anogenital and HPV-related diseases. Describe the biology, epidemiology, natural history, and immune response to HPV, as well as the societal costs associated with HPV infections. Apply consensus guidelines for cervical cancer screening and management of cervical abnormalities to the general population as well as those in special circumstances. Apply novel screening and management strategies to underserved and under-screened individuals (transgender, incarcerated, etc.). Apply colposcopy to the diagnosis and management of anogenital and HPV-related diseases in ways that reflect its usefulness and maximum benefits while minimizing potential harms. Diagnose and treat HPV-related diseases including those that affect the cervix, vagina, vulva, anus, and head/neck. . Identify strategies for prevention and screening of HPV-associated oropharyngeal disorders. Identify novel and experimental uses of therapeutic and prophylactic HPV vaccines, including the use of catch-up HPV immunization. Apply HPV testing and relevant diagnostic tests to clinical practice in a directed, evidence-based, cost-effective manner. Describe the vaginal microbiome and describe its impact on HPV clearance. Recognize the impact of implicit bias on patient care and learn techniques to identify and address this bias. Apply data on HPV ecology to screening and management of patients who are postmenopausal. Manage positive cytology and HPV test results, high risk HPV genotype results, and histologically confirmed anogenital neoplasia, reflecting current and future patient risk of high grade neoplasia.